Please login to the form below

Not currently logged in
Email:
Password:

BIND Therapeutics appoints Andrew Hirsch as permanent CEO

He had held the role on an interim basis since March

Andrew Hirsch BINDNanomedicine company BIND Therapeutics has appointed Andrew Hirsch as president and chief executive, confirming him in the roles he has held on an interim basis since March.

Prior to that Hirsch, who has now also been elected to BIND's board of directors, served as the Cambridge, Massachusetts-based company's chief operating officer and chief financial officer.

Before joining BIND Hirsch spent almost 10 years at Biogen, rising to VP of corporate strategy and M&A. Commenting on his role at BIND Hirsch said: “I'm excited by the opportunity to continue working with our employees, the senior management team and the Board as we develop therapies with the potential to have a profound impact on the treatment of serious diseases.

“Our nanomedicine platform, one of the most advanced in the industry, enables independent modulation of targeting, cellular trafficking and drug release. Together, these properties enable us to engineer novel therapeutic approaches that can lead to breakthrough therapies.”

The clinical-stage firm is developing targeted and programmable therapeutics called Accurins that it is working on developing into a pipeline of treatments for haematological and solid tumours. Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.

24th June 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics